阿帕他胺联合挽救性放疗和多西他赛强化治疗根治性前列腺切除术后前列腺特异性抗原复发性前列腺癌:2期STARTAR试验
STARTAR是一项多中心研究者发起的2期试验,纳入39例根治性前列腺切除术后PSA复发的前列腺癌患者,接受雄激素剥夺治疗联合阿帕他胺9个月、第8周开始挽救性放疗及6周期多西他赛。36个月无进展生存率为71%,显著优于历史对照的47%和STREAM试验的54%。
要点
- 36个月无进展生存率为71%,显著优于历史对照47%(p=0.004)和STREAM试验54%(p=0.039)。
- 常见任何级别不良事件包括潮热98%、疲乏88%、脱发77%、皮疹53%(3级10%)和发热性中性粒细胞减少5%。
- 所有患者均达到不可检测的PSA最低点。
核心结论
- 在高危PSA复发性前列腺癌中,雄激素剥夺治疗联合阿帕他胺、挽救性放疗和6周期多西他赛的3年无进展生存率提高至71%,表明治疗强化可行且有效,缓解持久性优于历史数据。
研究设计与样本
- STARTAR是一项多中心、研究者发起的2期试验,纳入39例根治性前列腺切除术后PSA复发的男性前列腺癌患者。
- 关键入选标准包括CT/骨扫描M0、Gleason 7伴T3/切缘阳性/N1疾病或Gleason 8-10前列腺腺癌、根治性前列腺切除术后4年内PSA复发(0.2-4 ng/ml)且阳性切除淋巴结少于4枚。
- 患者接受雄激素剥夺治疗联合阿帕他胺9个月,第8周开始放疗,随后接受6周期多西他赛。
- 主要终点为36个月无进展生存率及睾酮恢复,并与既往STREAM试验进行比较。
主要发现
- 入组39例男性,其中Gleason 8-10占46%,pN1占23%;中位PSA为0.58 ng/ml。
- 中位随访37个月,所有患者均达到不可检测的PSA最低点。
- 24个月和36个月无进展生存率分别为84%和71%,显著优于3年历史无进展生存率47%(p=0.004)和STREAM试验的恩扎卢胺/雄激素剥夺治疗/放疗无进展生存率54%(p=0.039)。
- 常见任何级别不良事件包括潮热98%、疲乏88%、脱发77%、皮疹53%(3级10%)和发热性中性粒细胞减少5%。
关键数值与推荐
- 36个月无进展生存率为71%,显著优于历史对照的3年无进展生存率47%(p=0.004)和STREAM试验的54%(p=0.039)。
- 24个月无进展生存率为84%。
- 中位随访37个月。
临床怎么用
- 作者认为,在高危PSA复发性前列腺癌中,雄激素剥夺治疗联合阿帕他胺、挽救性放疗和6周期多西他赛的治疗强化可行且有效,3年无进展生存率提高至71%,缓解持久性优于历史数据。
- 作者指出,术后治疗强化可为部分高危前列腺癌患者提供长期获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Androgen deprivation therapy (ADT) with salvage radiation therapy (RT) improves survival for patients with prostate-specific antigen (PSA) recurrence after radical prostatectomy (RP) for prostate cancer (PC), but many patients suffer further relapse. This study aims to determine the benefit of the combination of ADT, apalutamide, salvage RT, and docetaxel for high-risk PSA recurrent PC. METHODS: STARTAR is a multicenter, investigator-initiated phase 2 trial of men with PSA recurrent PC after RP. The key inclusion criteria included M0 by computed tomography/bone scan, Gleason 7 with either T3/positive margin/N1 disease or Gleason 8-10 prostate adenocarcinoma, PSA relapse (0.2-4 ng/ml) <4 yr after RP, and fewer than four positive resected lymph nodes. Patients received ADT with apalutamide for 9 mo, RT starting week 8, and then six cycles of docetaxel. The primary endpoint was 36-mo progression-free survival (PFS) with testosterone recovery and compared against the prior STREAM trial. KEY FINDINGS AND LIMITATIONS: We enrolled 39 men, including those with Gleason 8-10 (46%), pN1 (23%); the median PSA was 0.58 ng/ml. The median follow-up was 37 mo. All patients achieved undetectable PSA nadir. At 24 and 36 mo, PFS rates were 84% and 71%, respectively, which improved significantly over 3-yr 47% historic PFS and 54% enzalutamide/ADT/RT (STREAM) PFS rates (p = 0.004 and p = 0.039, respectively). Common any-grade adverse events included 98% hot flashes, 88% fatigue, 77% alopecia, 53% rash (10% G3), and 5% febrile neutropenia. CONCLUSIONS AND CLINICAL IMPLICATIONS: In this phase 2 trial of ADT, apalutamide, salvage RT, and six cycles of docetaxel for high-risk PSA recurrence, the 3-yr PFS rate improved to 71%, indicating feasible and efficacious treatment intensification, with durable remissions beyond historic data. PATIENT SUMMARY: Prostate cancer recurrence after surgical removal of the tumor occurs often, and current treatment options to limit recurrence after surgery are only partially effective. In this study, we found that the addition of an androgen receptor inhibitor and docetaxel chemotherapy to standard postsurgery radiation therapy and androgen deprivation therapy significantly improved progression-free survival at 3 yr after treatment. These results suggest that intensification of treatment after surgery can provide long-term benefit to a subset of patients with high-risk prostate cancer.
引用
- Zhang T, Howard L, Koontz BF, et al. Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial. Eur Urol Oncol. 2024. PMID: 38971644. doi:10.1016/j.euo.2024.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。